Syndax Pharmaceuticals (SNDX) Competitors

Syndax Pharmaceuticals logo
$9.13 -0.32 (-3.39%)
As of 11/16/2026 04:00 PM Eastern

SNDX vs. LEGN, ACAD, DYN, CELC, and TLX

Should you buy Syndax Pharmaceuticals stock or one of its competitors? Syndax Pharmaceuticals's main competitors and comparable companies include Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Syndax Pharmaceuticals compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Legend Biotech currently has a consensus price target of $50.85, indicating a potential upside of 217.99%. Syndax Pharmaceuticals has a consensus price target of $41.60, indicating a potential upside of 355.64%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Legend Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Legend Biotech has a net margin of -0.02% compared to Syndax Pharmaceuticals' net margin of -72.32%. Legend Biotech's return on equity of -0.03% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-0.02% -0.03% -0.02%
Syndax Pharmaceuticals -72.32%-804.38%-34.93%

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Syndax Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$1.03B3.01-$296.80M-$0.01N/A
Syndax Pharmaceuticals$289.68M2.84-$285.42M-$2.36N/A

Legend Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

In the previous week, Legend Biotech had 34 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 39 mentions for Legend Biotech and 5 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.14 beat Legend Biotech's score of -0.09 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
14 Neutral mention(s)
9 Negative mention(s)
2 Very Negative mention(s)
Neutral
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Legend Biotech beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to ACADIA Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$289.68M2.84-$285.42M-$2.36N/A
ACADIA Pharmaceuticals$1.07B3.01$391M$2.118.85

ACADIA Pharmaceuticals has a net margin of 30.13% compared to Syndax Pharmaceuticals' net margin of -72.32%. ACADIA Pharmaceuticals' return on equity of 8.90% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals-72.32% -804.38% -34.93%
ACADIA Pharmaceuticals 30.13%8.90%6.86%

Syndax Pharmaceuticals presently has a consensus price target of $41.60, indicating a potential upside of 355.64%. ACADIA Pharmaceuticals has a consensus price target of $31.34, indicating a potential upside of 67.87%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
ACADIA Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72

Syndax Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 5 mentions for Syndax Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.27 beat Syndax Pharmaceuticals' score of 0.14 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ACADIA Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

ACADIA Pharmaceuticals beats Syndax Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Dyne Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Syndax Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
Syndax Pharmaceuticals$289.68M2.84-$285.42M-$2.36N/A

Dyne Therapeutics currently has a consensus price target of $31.29, indicating a potential upside of 87.34%. Syndax Pharmaceuticals has a consensus price target of $41.60, indicating a potential upside of 355.64%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Dyne Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -72.32%. Dyne Therapeutics' return on equity of -69.73% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
Syndax Pharmaceuticals -72.32%-804.38%-34.93%

In the previous week, Dyne Therapeutics had 10 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 15 mentions for Dyne Therapeutics and 5 mentions for Syndax Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.26 beat Syndax Pharmaceuticals' score of 0.14 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Celcuity?

Celcuity (NASDAQ:CELC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Celcuity has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -72.32%. Syndax Pharmaceuticals' return on equity of -804.38% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
CelcuityN/A -1,522.54% -42.11%
Syndax Pharmaceuticals -72.32%-804.38%-34.93%

In the previous week, Celcuity had 2 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 7 mentions for Celcuity and 5 mentions for Syndax Pharmaceuticals. Celcuity's average media sentiment score of 0.42 beat Syndax Pharmaceuticals' score of 0.14 indicating that Celcuity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celcuity
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

63.3% of Celcuity shares are held by institutional investors. 13.3% of Celcuity shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Celcuity has higher earnings, but lower revenue than Syndax Pharmaceuticals. Celcuity is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CelcuityN/AN/A-$177.04M-$4.71N/A
Syndax Pharmaceuticals$289.68M2.84-$285.42M-$2.36N/A

Celcuity currently has a consensus target price of $151.79, suggesting a potential upside of 150.60%. Syndax Pharmaceuticals has a consensus target price of $41.60, suggesting a potential upside of 355.64%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Celcuity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity
2 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.69
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Syndax Pharmaceuticals beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Telix Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Syndax Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$289.68M2.84-$285.42M-$2.36N/A
Telix Pharmaceuticals$803.79M3.78-$7.12MN/AN/A

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.82 beat Syndax Pharmaceuticals' score of 0.14 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Telix Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Syndax Pharmaceuticals currently has a consensus price target of $41.60, suggesting a potential upside of 355.64%. Telix Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 129.82%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Telix Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Telix Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -72.32%. Telix Pharmaceuticals' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals-72.32% -804.38% -34.93%
Telix Pharmaceuticals N/A N/A N/A

Summary

Telix Pharmaceuticals beats Syndax Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNDX vs. The Competition

MetricSyndax PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$850.77M$4.15B$7.84B$12.17B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio-3.8727.6734.7128.60
Price / Sales2.8416.368.635.70
Price / CashN/A26.3721.9322.50
Price / Book-48.054.074.323.70
Net Income-$285.42M-$22.86M$3.52B$392.17M
7 Day Performance-3.79%-6.13%-4.44%-3.21%
1 Month Performance-29.22%-4.90%-3.49%-5.66%
1 Year Performance-46.86%-2.99%0.19%-5.97%

Syndax Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNDX
Syndax Pharmaceuticals
2.5974 of 5 stars
$9.13
-3.4%
$41.60
+355.6%
-45.1%$850.77M$289.68MN/A298
LEGN
Legend Biotech
3.3916 of 5 stars
$17.50
-5.6%
$50.85
+190.5%
-47.2%$3.39B$1.03BN/A2,965
ACAD
ACADIA Pharmaceuticals
4.7604 of 5 stars
$18.75
+3.4%
$31.34
+67.2%
-22.3%$3.24B$1.07B8.89798
DYN
Dyne Therapeutics
3.2417 of 5 stars
$17.16
+0.9%
$31.29
+82.3%
-11.1%$3.21BN/AN/A258
CELC
Celcuity
2.6768 of 5 stars
$64.37
+0.3%
$151.79
+135.8%
-34.6%$3.16BN/AN/A155

Related Companies and Tools


This page (NASDAQ:SNDX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners